KPRX vs CETX Comparison

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.